THESAN PHARMACEUTICALS APPOINTS DR. BHASKAR CHAUDHURI TO THE BOARD OF DIRECTORS AUGUST 2014

SAN DIEGO, CA, Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy. He also serves on the Board of multiple pharmaceutical companies.

Click to download press release pdf file

Press release Thesan 101712 final Download PDF

THESAN PHARMACEUTICALS ANNOUNCES A $49M SERIES B FINANCING FEBRUARY 2014

SAN DIEGO, CA, Thesan Pharmaceuticals announced today the closing of a $49M Series B financing, led by Novo Ventures (a current Investor), with SV Life Sciences and Lundbeckfond Ventures joining Novartis Venture Fund in the syndicate. Thesan’s mission is the development of novel approaches for the treatment of dermatological disorders, including acne and atopic dermatitis.

Click to download press release pdf file

Press Release Feb 24 2014 FINAL Download PDF

THESAN PHARMACEUTICALS ANNOUNCES SERIES A FUNDING CO-LED BY NOVO VENTURES AND NOVARTIS VENTURE FUNDS. OCTOBER 2012

SAN DIEGO, CA, Thesan Pharmaceuticals announced the closing of a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company will focus on the development of novel approaches for the treatment of dermatological disorders. The lead drug candidate is a topically-applied new chemical entity expected to enter the clinic in 2013.

Click to download press release pdf file

Press release Thesan 101712 final Download PDF